Century Therapeutics, Inc.
IPSC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850119
In the last 90 days, Century Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 100 institutions reported holding it in 13F filings for Q2 2026, worth $387.0M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Century Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 50 | 52 | +2 |
| Shares | 21.1M | 22.2M | +1.01M (+4.8%) |
| Value | $335.2M | $278.9M | −$56.3M (−16.8%) |
New holders (8)
Institutions that held Century Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 32,458 | $409.0K | 0.00% |
| Rhumbline Advisers | 14,961 | $188.0K | 0.00% |
| MetLife Investment Management | 12,167 | $153.2K | 0.00% |
| Parametric Portfolio Associates LLC | 11,589 | $146.0K | 0.00% |
| Barclays PLC | 2,815 | $36.0K | 0.00% |
| Amalgamated Bank | 1,720 | $22.0K | 0.00% |
| Amalgamated Financial Corp. | 1,720 | $22.0K | 0.00% |
| Metropolitan Life Insurance Co | 1,426 | $18.0K | 0.00% |
Sold out (6)
Institutions that held Century Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| OrbiMed Advisors LLC | 307,047 | $4.87M |
| Parametrica Management Ltd | 28,855 | $459.0K |
| Royce & Associates LP | 12,900 | $205.0K |
| Schonfeld Strategic Advisors LLC | 12,300 | $195.0K |
| ProShare Advisors LLC | 10,273 | $163.0K |
| Advisor Group Holdings, Inc. | 200 | $3.00K |